168 related articles for article (PubMed ID: 12358914)
1. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma.
Molin D; Edström A; Glimelius I; Glimelius B; Nilsson G; Sundström C; Enblad G
Br J Haematol; 2002 Oct; 119(1):122-4. PubMed ID: 12358914
[TBL] [Abstract][Full Text] [Related]
2. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.
Molin D; Fischer M; Xiang Z; Larsson U; Harvima I; Venge P; Nilsson K; Sundström C; Enblad G; Nilsson G
Br J Haematol; 2001 Sep; 114(3):616-23. PubMed ID: 11552987
[TBL] [Abstract][Full Text] [Related]
3. [Tryptase- and chymase-positive mast cells as possible prognostic factor in patients with Hodgkin's lymphoma].
Rygoł B; Kyrcz-Krzemień S; Pajiak J; Konicki P; Kowai E; Gasińska T
Pol Arch Med Wewn; 2007; 117(1-2):27-32. PubMed ID: 17642203
[TBL] [Abstract][Full Text] [Related]
4. Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.
Molin D
Ups J Med Sci; 2004; 109(3):179-228. PubMed ID: 15508524
[TBL] [Abstract][Full Text] [Related]
5. Expression of mast cell tryptases in Hodgkin and Reed-Sternberg (HRS) cells.
Carvalho RF; Mahshid Y; Claesson HE; Glimelius I; Fischer M; Nilsson G
Scand J Immunol; 2008 Jan; 67(1):53-6. PubMed ID: 18021188
[TBL] [Abstract][Full Text] [Related]
6. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
Hsu PL; Hsu SM
Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
[TBL] [Abstract][Full Text] [Related]
7. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
[TBL] [Abstract][Full Text] [Related]
8. Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.
Andersen MD; Kamper P; Nielsen PS; Bendix K; Riber-Hansen R; Steiniche T; Hamilton-Dutoit S; Clausen M; d'Amore F
Eur J Haematol; 2016 Mar; 96(3):252-9. PubMed ID: 25963595
[TBL] [Abstract][Full Text] [Related]
9. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
10. Fibrosis in Hodgkin and non-Hodgkin lymphomas.
Tataroglu C; Sarioglu S; Kargi A; Ozkal S; Aydin O
Pathol Res Pract; 2007; 203(10):725-30. PubMed ID: 17804176
[TBL] [Abstract][Full Text] [Related]
11. Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's lymphoma--a population-based study.
Glimelius I; Rubin J; Rostgaard K; Amini RM; Simonsson M; Sorensen KM; Smedby KE; Venge P; Hjalgrim H; Molin D; Enblad G
Eur J Haematol; 2011 Sep; 87(3):208-16. PubMed ID: 21623917
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
Vandenberghe P; Wlodarska I; Tousseyn T; Dehaspe L; Dierickx D; Verheecke M; Uyttebroeck A; Bechter O; Delforge M; Vandecaveye V; Brison N; Verhoef GE; Legius E; Amant F; Vermeesch JR
Lancet Haematol; 2015 Feb; 2(2):e55-65. PubMed ID: 26687610
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's lymphoma is a rare form of clonal haematological non-mast cell disease in systemic mastocytosis.
Gasljevic G; Grcar-Kuzmanov B; Grosel A; Sever M; Gazic B; Kloboves-Prevodnik V
Diagn Pathol; 2015 Mar; 10():5. PubMed ID: 25881198
[TBL] [Abstract][Full Text] [Related]
14. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
15. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
16. CD30 expression in L&H cells of Hodgkin's disease, nodular lymphocyte predominant type.
Ranjan P; Naresh KN
Histopathology; 2003 Apr; 42(4):406-7. PubMed ID: 12653955
[No Abstract] [Full Text] [Related]
17. Immunohistochemical detection of CD30 remains negative in nodular lymphocyte-predominant Hodgkin's disease using enhanced antigen retrieval.
Roberts C; Jack F; Angus B; Reid A; Thompson WD
Histopathology; 2002 Feb; 40(2):166-70. PubMed ID: 11952861
[TBL] [Abstract][Full Text] [Related]
18. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line.
Pinto A; Aldinucci D; Gloghini A; Zagonel V; Degan M; Improta S; Juzbasic S; Todesco M; Perin V; Gattei V; Herrmann F; Gruss HJ; Carbone A
Blood; 1996 Nov; 88(9):3299-305. PubMed ID: 8896393
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma.
Fukushima N; Satoh T; Sano M; Tokunaga O
Leuk Lymphoma; 2001 Aug; 42(4):709-20. PubMed ID: 11697501
[TBL] [Abstract][Full Text] [Related]
20. A quantitative study of mast cells in Hodgkin's disease.
Crocker J; Smith PJ
J Clin Pathol; 1984 May; 37(5):519-22. PubMed ID: 6725599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
